UCB – UCB Biopharma

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe immune-mediated inflammatory and neurological diseases. This is powered by the approximately 9,000 people – from our headquarters in Brussels, Belgium to across nearly 40 countries worldwide.

What is the role of UCB in Autopix

UCB will be contributing clinical study data and expertise in the field of computational image analysis, data management and computing infrastructure. Our efforts will be focused on developing AI models for differential diagnosis, monitoring, and prediction of inflammation and structural outcomes in spine and sacroiliac joints in axial spondyloarthritis.

Q&A

In what part of the patient journey will your institution most likely contribute?

UCB will contribute to improving the (differential) diagnosis, prediction and therapeutic monitoring of patients living with axial spondyloarthritis, psoriatic arthritis and rheumatoid arthritis.

What long-term impacts do you envision of your contribution?

We aim to deliver AI-driven tools that can be leveraged in routine clinical care and in clinical studies in patients with axSpA and PsA. For an individual patient, it will be critical to deliver AI tools and imaging methodologies that will shorten time to correct diagnosis and improve the prediction of treatment outcome, and ultimately ensure the best available treatment to control disease burden and progression.

Why is it so important?

Transforming the life of patients living with rheumatic diseases requires the scale achieved by partnering with leading academic institutions, healthcare industry and patients, bringing together different expertise and the necessary resources.